Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.37 |
| ▸ | CDK2 | P24941 | 4/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 3/20 | 0.30 |
| ▸ | HCK | P08631 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11916288 | 0.81 | KDM4E (0.36) | ABL1SRCHCKPIM1 | |
| SCHEMBL23508176 | 0.80 | SRC (0.30) | ABL1SRCHCKPIM1 | |
| SCHEMBL15719036 | 0.80 | POLB (0.41) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL23508201 | 0.80 | GSK3B (0.36) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL10359833 | 0.78 | SRC (0.33) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL23381889 | 0.78 | POLB (0.33) | — | |
| SCHEMBL14194712 | 0.78 | TP53 (0.33) | ABL1SRC | |
| SCHEMBL15224428 | 0.78 | CDK2 (0.34) | CDK2CCNA2ABL1SRCHCK | |
| SCHEMBL14194710 | 0.76 | LRRK2 (0.32) | — | |
| SCHEMBL31153817 | 0.76 | CDK2 (0.46) | CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250066370-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCH (DE) | 2025-02-27 | — | — | US | disclosed |
| EP-4463458-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | Deutsches Krebsforschungszentrum (DE) | 2024-11-20 | — | — | EP | disclosed |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-118541372-A | Bicyclic triazine derivatives for the treatment of cancer | 德国癌症研究中心 | 2024-08-23 | — | — | CN | disclosed |
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2023135057-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2023-07-20 | — | — | WO | disclosed |
| US-20230192700-A1 | PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20110206661-A1 | TRIMETHOXYPHENYL INHIBITORS OF TYROSINE KINASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| EP-1438039-A2 | PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-21 | — | — | EP | disclosed |
| US-20040138245-A1 | Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-15 | — | — | US | disclosed |
| US-20040048849-A1 | Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors | IPSEN PHARMA S.A.S. (FR) | 2004-03-11 | — | — | US | disclosed |
| EP-1345941-A1 | CYCLIN-DEPENDENT KINASE (CDK) AND GLYCOLENE SYNTHASE KINASE-3 (GSK-3) INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002096348-A2 | PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002050079-A1 | CYCLIN-DEPENDENT KINASE (CDK) AND GLYCOLENE SYNTHASE KINASE-3 (GSK-3) INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-06-27 | — | — | WO | disclosed |
| EP-0122978-B1 | THERAPEUTICALLY ACTIVE DI-, TRI-, TETRA- AND PENTA-AZA INDENES | BIOMEASURE, INC. (US) | 1988-05-18 | — | — | EP | disclosed |
| US-4565815-A | Pyrazolo[1,5-a]-1,3,5-triazines | BIOMEASURE, INC. (US) | 1986-01-21 | — | — | US | disclosed |
| EP-0122978-A1 | Therapeutically active di-, tri-, tetra- and penta-aza indenes | BIOMEASURE, INC. (US) | 1984-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206661-A1 | TRIMETHOXYPHENYL INHIBITORS OF TYROSINE KINASE | ABL1, LCK, SRC | GSK3B 229/4885CDK2 186/4885CHEK1 425/4885 |
| US-20040048849-A1 | Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors | CDK1, CDK3, CDKL3 | GSK3B 25/4885CDK2 12/4885CHEK1 89/4885 |
| US-20250066370-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | BRCA1, CCNY, CCND2 | GSK3B 1582/4885CDK2 45/4885CHEK1 287/4885 |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | GSK3B 489/4885CDK2 1444/4885CHEK1 3921/4885 |
| US-20230192700-A1 | PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12 | CDK12, CDK1, CDK15 | GSK3B 175/4885CDK2 4/4885CHEK1 59/4885 |
| US-20040138245-A1 | Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment | DTYMK, DGKG, DGKZ | GSK3B 2441/4885CDK2 567/4885CHEK1 165/4885 |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | GSK3B 489/4885CDK2 1444/4885CHEK1 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.